Market Closed - Nasdaq 04:30:00 2024-04-25 pm EDT 5-day change 1st Jan Change
0.504 USD +0.40% Intraday chart for Orgenesis Inc. -1.58% +0.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Powell Comments, -2- DJ
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility CI
North American Morning Briefing : Stocks Seen -2- DJ
North American Morning Briefing : Markets Steady -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Orgenesis Inc. announced that it has received $2.340901 million in funding CI
Orgenesis Inc. announced that it expects to receive $2.340901 million in funding CI
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P. CI
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P. CI
Alimera Sciences Appoints New CFO MT
Earnings Flash (ORGS) ORGENESIS Reports Q3 Revenue $110,000 MT
Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Investors Weigh -2- DJ
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon MT
Sector Update: Health Care Stocks Lower in Afternoon Trading MT
Orgenesis Prices $1.1 Million Registered Direct Offering MT
Orgenesis Inc. announced that it expects to receive $1.1 million in funding CI
Orgenesis Scraps Planned Public Offering of Units Due to Market Conditions MT
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States CI
Orgenesis Inc. announced that it has received $1 million in funding CI
Transcript : Orgenesis Inc., Q2 2023 Earnings Call, Aug 11, 2023
North American Morning Briefing : Stock Futures -2- DJ
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020. CI
Orgenesis Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart Orgenesis Inc.
More charts
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
More about the company
  1. Stock Market
  2. Equities
  3. ORGS Stock
  4. News Orgenesis Inc.
  5. Earnings Flash (ORGS) ORGENESIS Posts Q2 Revenue $7.2M